Abdominal aortic aneurysm screening, what the guidelines actually say

Most of the screenings in this tracker apply, in some form, to a broad slice of adults. Abdominal aortic aneurysm screening does not, and the U.S. Preventive Services Task Force is unusually explicit about that limit: this is a narrow, one-time test for a specific group, not a general screening recommended for everyone past a certain age.

What this screening is and what it looks for

An abdominal aortic aneurysm is an abnormal widening of the aorta, the body’s main artery, as it passes through the abdomen. Most AAAs cause no symptoms and are found incidentally or through screening; the danger is rupture, which the USPSTF notes carries a high case-fatality rate. The screening test itself is a single abdominal ultrasound, a quick, noninvasive scan that measures the diameter of the aorta. It is not a repeated test in the way a mammogram or colonoscopy is; for someone who screens negative, the Task Force’s recommendation is for one scan, not an ongoing schedule.

Who and when, per the USPSTF

The 2019 recommendation does not give one answer for “who should be screened.” It gives four different answers, split by sex and smoking history, and the differences between them are the point:

• Men 65 to 75 who have ever smoked: Grade B. The Task Force recommends one-time ultrasound screening, concluding with moderate certainty that it has a moderate net benefit.
• Men 65 to 75 who have never smoked: Grade C. Rather than a routine recommendation, the Task Force says clinicians should selectively offer screening, based on professional judgment and a person’s preferences, because the net benefit in this narrower group is judged small rather than moderate.
• Women who have never smoked and have no family history of AAA: Grade D. The Task Force recommends against routine screening in this group, concluding with moderate certainty that the harms equal or exceed any benefit.
• Women 65 to 75 who have ever smoked or have a family history of AAA: Grade I. The Task Force states the current evidence is insufficient to weigh the balance of benefits and harms, and does not issue a for-or-against recommendation.

Only the first of these, men aged 65 to 75 who have ever smoked, carries the moderate-certainty Grade B this page’s facts panel reflects; that population is also the one guideline row this tracker’s underlying dataset carries for AAA screening, and it is the only population this page’s frontmatter describes. The other three populations exist and are part of the same recommendation statement, but they are graded differently and are not the same guideline eligibility as the Grade B group. These grades describe guideline eligibility and the strength of the evidence behind each group, not an instruction that any particular person should be screened. Whether AAA screening is appropriate for you, especially outside the Grade B group, is a conversation for a clinician who knows your smoking history, family history, and overall risk.

The evidence and its grade

The case for screening men who have ever smoked rests on randomized trial evidence: several trials found that one-time ultrasound screening in older men reduced AAA-related mortality, with the benefit concentrated in current and former smokers, because AAA is substantially more common in that group than in men who never smoked. That is also why the Task Force splits men by smoking status rather than treating “men 65 to 75” as one population: the same test performed on a lower-prevalence group finds fewer aneurysms per person screened, which shifts the benefit-to-harm balance enough to move the grade from B to C.

For women, the evidence base is thinner across the board. AAA is less common in women generally, and the trials that established a mortality benefit in men enrolled few women, so the Task Force cannot extend the same moderate-certainty conclusion to any subgroup of women. For women who never smoked and have no family history, the low prevalence tips the Task Force toward Grade D, recommending against routine screening because the harms of a low-yield test, mainly the anxiety and downstream procedures from a false-positive or borderline finding, are judged to outweigh a benefit unlikely to materialize. For women who have smoked or have a family history, prevalence is presumably higher, but the Task Force says there simply is not enough direct evidence in that specific group to reach a conclusion either way, hence Grade I rather than a for-or-against grade.

Where the guidance differs

The USPSTF is not the only body with a AAA screening position, and the differences are concrete rather than semantic. In the United Kingdom, the National Health Service’s AAA screening programme invites every man in the year he turns 65, regardless of smoking history, an unconditional-by-sex, unconditional-by-smoking approach that the USPSTF’s grade structure explicitly does not support for U.S. practice. In the United States, the Society for Vascular Surgery’s 2018 practice guidelines recommend one-time ultrasound screening in men or women aged 65 to 75 with a history of tobacco use, plus screening for first-degree relatives of someone with a known AAA, a position that reaches further than the USPSTF’s Grade I “insufficient evidence” for women who have smoked or have a family history. None of these bodies has more raw data than the others; they are reading a thin evidence base, thinnest for women, and drawing different lines about how much certainty is required before recommending a population-wide test. That is an honest disagreement, not an error.

Questions to ask your clinician

Framed as questions to bring to a visit, not as steps to take on your own:

• Am I in the men-65-to-75-who-have-ever-smoked group the Grade B recommendation covers, or do I fall into one of the other three groups with a different grade?
• I am a man in this age range who never smoked; how should I think about the Task Force’s “selectively offer” language, and what would make screening a reasonable choice for me specifically?
• I am a woman with a smoking history or a family history of AAA; what does it mean that the evidence here is officially insufficient rather than for or against, and how should that shape a decision with my clinician?
• If a one-time screening ultrasound finds a small aneurysm, what happens next, and is any further monitoring or action based on its size?
• Does anything else in my history, a connective tissue disorder or other vascular disease, put me outside this general guideline and into an individualized screening plan?

You can compare this profile against the full Guideline Tracker, read the sibling profile for hypertension screening, or see how everyday choices fit alongside screening in the big levers.